Plant Name: Nuxia oppositifolia
Taxonomic Information:
Plant ID: NPO25196
Plant Latin Name: Nuxia oppositifolia
Taxonomy Genus: Nuxia
Taxonomy Family: Stilbaceae
Plant External Links:
NCBI TaxonomyDB:
257432
Plant-of-the-World-Online:
546840-1
Used in Medicines:
Unknown.
Geographical Distribution:
Eritrea; Madagascar; Angola; Uganda; South Africa; Sudan; Tanzania; Saudi Arabia; Zambia; Ethiopia; Djibouti; Zimbabwe; Mozambique; Somalia; Swaziland; Namibia; Kenya; Yemen; Malawi
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| NPSR1; | |
| PIM1; IGF1R; FLT3; AURKB; AXL; CDK1; MET; MAP2K1; KDR; | |
| ALOX12; NOX4; HSD17B10; POLB; | |
| PTGS2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | Q02750 | CHEMBL3587 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 8.333E-09 | 1.650E-05 | AXL, FLT3, IGF1R, KDR, MAP2K1, MET |
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 2.473E-07 | 2.071E-04 | ALOX12, AURKB, AXL, CDK1, IGF1R, KDR, PIM1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 5.729E-07 | 4.455E-04 | AURKB, FLT3, IGF1R, KDR, PIM1 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 1.206E-06 | 9.059E-04 | AURKB, AXL, CDK1, FLT3, IGF1R, KDR, MAP2K1, MET, PIM1 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 4.095E-06 | 1.621E-03 | CYP1B1, CYP2C19, NOX4, PTGS2 |
| BP | GO:0032502; developmental process | GO:0045766; positive regulation of angiogenesis | 8.530E-06 | 2.575E-03 | ALOX12, CYP1B1, KDR, PTGS2 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 7.853E-06 | 2.575E-03 | CYP1B1, CYP2C19, NOX4 |
| CC | GO:0043226; organelle | GO:0005876; spindle microtubule | 1.291E-05 | 3.604E-03 | AURKB, CDK1, POLB |
| MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 1.527E-05 | 4.055E-03 | FLT3, KDR |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 1.975E-05 | 4.886E-03 | AXL, CDK1, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0007569; cell aging | 2.391E-05 | 5.481E-03 | CDK1, MAP2K1, NOX4 |
| BP | GO:0008152; metabolic process | GO:0051054; positive regulation of DNA metabolic process | 3.057E-05 | 6.590E-03 | AURKB, CDK1, IGF1R, NOX4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.267E-05 | 6.971E-03 | CYP1B1, CYP2C19 |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 3.825E-05 | 7.785E-03 | AXL, CDK1, FLT3 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 3.631E-21 | 6.391E-19 | CA12, CA1, CA3, CA2, CA5A, CA4, CA7, CA6, CA9, CA14 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 3.458E-13 | 3.043E-11 | CAMK2B, MAP2K1, SRC, MMP2, PIK3R1, HIF1A, MMP9, PTK2, IGF1R, KDR, AKT1, TP53, MET |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 9.287E-12 | 5.448E-10 | GSK3B, MAP2K1, FLT3, DAPK1, MMP2, PIK3R1, PTGS2, HIF1A, MMP9, NFKB1, PTK2, IGF1R, AKT1, MET, TP53 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 5.131E-10 | 2.258E-08 | ALOX5, HSD17B2, CYP1A1, CYP1B1, PTGS2, CYP19A1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 2.172E-09 | 6.139E-08 | MAP2K1, SRC, KDR, AKT1, PIK3R1, PTGS2, PTK2 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 2.441E-09 | 6.139E-08 | CYP2C8, PLA2G1B, ALOX5, ALOX15, ALOX12, CYP2C19, PTGS2 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 4.256E-09 | 9.364E-08 | MAP2K1, FLT3, AKT1, PIK3R1, TP53, MET, HIF1A |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 6.673E-09 | 1.261E-07 | CYP2C8, MAP2K1, MAOA, ALOX5, ALOX15, ALOX12, CYP2C19, PTGS2 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 7.829E-10 | 2.756E-08 | CYP2C8, PLA2G1B, CYP1A2, ALOX15, CYP3A4, CYP2C19 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 3.602E-08 | 4.226E-07 | GSK3B, MAP2K1, KDR, AKT1, PIK3R1, PKN1, TP53, MET, PTK2, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 3.167E-08 | 3.982E-07 | GSK3B, MAP2K1, AKT1, PIK3R1, TP53, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 7.163E-09 | 1.261E-07 | MAP2K1, DAPK1, SRC, MMP2, MMP9, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 1.658E-08 | 2.615E-07 | FLT3, MMP3, TP53, MPO, MMP9, MET, NFKB1, PTK2, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 2.701E-08 | 3.657E-07 | CAMK2B, GSK3B, MAP2K1, SRC, AKT1, PIK3R1, PTK2 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 4.495E-08 | 4.945E-07 | GSK3B, MAP2K1, SRC, KDR, AKT1, PIK3R1, MET, PTK2, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 5.366E-08 | 5.402E-07 | MAP2K1, SRC, AKT1, STAT6, PIK3R1, TP53, MMP9, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.783E-08 | 2.615E-07 | CYP2C8, CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP2C19, PTGS2 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 5.525E-08 | 5.402E-07 | MAP2K1, FLT3, PIM1, AKT1, PIK3R1, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 8.752E-08 | 7.702E-07 | CAMK2B, MAP2K1, AKT1, PIK3R1, HIF1A, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 1.229E-07 | 1.030E-06 | CAMK2B, MAP2K1, AKT1, PIK3R1, TP53, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 1.378E-07 | 1.102E-06 | MAP2K1, MMP3, AKT1, PIK3R1, PTGS2, MMP9, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 2.231E-07 | 1.605E-06 | GSK3B, MAP2K1, SRC, AKT1, PIK3R1, TP53, HIF1A |
| 09150 Organismal Systems | 09151 Immune system | hsa04062 | Chemokine signaling pathway | 3.610E-07 | 2.353E-06 | GSK3B, MAP2K1, CXCR1, SRC, AKT1, PIK3R1, NFKB1, PTK2 |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 2.096E-07 | 1.604E-06 | MAP2K1, AKT1, PIK3R1, TP53, MET, IGF1R |
| 09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 2.503E-07 | 1.695E-06 | CAMK2B, GSK3B, MAP2K1, AKT1, PIK3R1, TP53, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 2.280E-07 | 1.605E-06 | GSK3B, MAP2K1, SRC, AKT1, PIK3R1, NFKB1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 6.145E-08 | 5.692E-07 | CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP3A4, CYP19A1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 5.868E-07 | 3.689E-06 | GSK3B, CSNK2A1, AKT1, RAB9A, PIK3R1, TP53, NFKB1 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.373E-06 | 7.550E-06 | PLA2G1B, MAOA, ALOX15, AKR1B1, ALOX12, PYGL, PTGS2, CYP2C19, CYP3A4, CYP19A1, HSD17B10, CYP2C8, ALOX5, HSD17B2, CYP1A2, CYP1A1, XDH |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.167E-06 | 6.793E-06 | MAP2K1, ABCC1, PIM1, CYP1B1, PTGS2, TP53, MMP9, MET, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 1.560E-06 | 8.077E-06 | MAP2K1, PLA2G1B, KDR, AKT1, PIK3R1, MET, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 6.594E-07 | 4.002E-06 | AKT1, PIK3R1, PTGS2, TP53, NFKB1, PTK2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.515E-06 | 8.077E-06 | MAP2K1, SRC, MMP2, AKT1, PIK3R1, MMP9 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 8.168E-06 | 3.343E-05 | GSK3B, CSNK2A1, CDK1, AKT1, PIK3R1, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 1.085E-05 | 4.340E-05 | MAP2K1, SRC, KDR, AKT1, PIK3R1, MET, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 4.653E-06 | 2.100E-05 | MAP2K1, ABCC1, AKT1, PIK3R1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 1.196E-06 | 6.793E-06 | GSK3B, MAP2K1, AKT1, PIK3R1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 1.739E-06 | 8.744E-06 | ALK, MAP2K1, AKT1, PIK3R1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 3.956E-06 | 1.832E-05 | MAP2K1, AKT1, PIK3R1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 2.897E-06 | 1.416E-05 | GSK3B, MAP2K1, AKT1, PIK3R1, TP53 |
| 09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 6.521E-06 | 2.733E-05 | GSK3B, MAP2K1, AKT1, PIK3R1, NFKB1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 3.181E-05 | 1.166E-04 | MMP2, PIM1, AKT1, PIK3R1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 3.956E-06 | 1.832E-05 | MAP2K1, AKT1, PIK3R1, MET, HIF1A |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 6.521E-06 | 2.733E-05 | MAP2K1, AKT1, PIK3R1, TP53, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 2.750E-05 | 1.030E-04 | MAP2K1, CDK1, AKT1, PIK3R1, IGF1R |
| 09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 2.248E-05 | 8.600E-05 | AKT1, PIK3R1, TP53, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 9.593E-05 | 3.247E-04 | POLB, SRC, CDK1, PIK3R1, TP53, NFKB1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 4.934E-06 | 2.171E-05 | CYP2C8, MAOA, CYP1A2, CYP3A4, CYP2C19 |
| 09150 Organismal Systems | 09151 Immune system | hsa04660 | T cell receptor signaling pathway | 3.662E-05 | 1.315E-04 | GSK3B, MAP2K1, AKT1, PIK3R1, NFKB1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 4.588E-05 | 1.615E-04 | GSK3B, AKT1, PIK3R1, PYGL, NFKB1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04728 | Dopaminergic synapse | 1.022E-04 | 3.395E-04 | CAMK2B, GSK3B, MAOA, AKT1, DRD4 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 1.181E-04 | 3.778E-04 | GSK3B, AKT1, PIK3R1, TP53, NFKB1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 1.502E-04 | 4.406E-04 | MAP2K1, AKT1, PIK3R1, TP53, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04910 | Insulin signaling pathway | 1.453E-04 | 4.381E-04 | GSK3B, MAP2K1, AKT1, PIK3R1, PYGL |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.605E-04 | 4.632E-04 | GSK3B, MAP2K1, AKT1, PIK3R1, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04921 | Oxytocin signaling pathway | 2.638E-04 | 7.369E-04 | CAMK2B, MAP2K1, SRC, PIK3R1, PTGS2 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05166 | HTLV-I infection | 3.333E-04 | 9.025E-04 | POLB, GSK3B, AKT1, PIK3R1, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05164 | Influenza A | 4.220E-04 | 1.125E-03 | GSK3B, MAP2K1, AKT1, PIK3R1, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 7.560E-04 | 1.874E-03 | CAMK2B, MAP2K1, AKT1, PIK3R1, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04912 | GnRH signaling pathway | 3.258E-04 | 8.958E-04 | CAMK2B, MAP2K1, SRC, MMP2 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 6.915E-04 | 1.739E-03 | CAMK2B, MAP2K1, AKT1, PIK3R1 |
| 09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 4.320E-04 | 1.135E-03 | CAMK2B, SRC, ALOX12, PIK3R1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04620 | Toll-like receptor signaling pathway | 5.814E-04 | 1.483E-03 | MAP2K1, AKT1, PIK3R1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05231 | Choline metabolism in cancer | 4.844E-04 | 1.254E-03 | MAP2K1, AKT1, PIK3R1, HIF1A |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 8.854E-05 | 3.056E-04 | CYP2C8, CYP1A2, CYP1A1, CYP3A4 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 1.056E-04 | 3.443E-04 | CXCR1, SRC, MET, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 8.695E-04 | 2.096E-03 | ALOX5, AKT1, PIK3R1, NFKB1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04114 | Oocyte meiosis | 1.015E-03 | 2.414E-03 | CAMK2B, MAP2K1, CDK1, IGF1R |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.393E-04 | 4.301E-04 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09150 Organismal Systems | 09158 Development | hsa04380 | Osteoclast differentiation | 1.318E-03 | 3.020E-03 | MAP2K1, AKT1, PIK3R1, NFKB1 |
| 09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 2.420E-03 | 5.010E-03 | CXCR1, SRC, KDR, MET, IGF1R |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 1.469E-04 | 4.381E-04 | CSNK2A1, SRC, MET, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04310 | Wnt signaling pathway | 1.724E-03 | 3.793E-03 | CAMK2B, GSK3B, CSNK2A1, TP53 |
| 09150 Organismal Systems | 09151 Immune system | hsa04670 | Leukocyte transendothelial migration | 8.695E-04 | 2.096E-03 | MMP2, PIK3R1, MMP9, PTK2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 1.355E-03 | 3.059E-03 | MAP2K1, AKT1, PIK3R1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04072 | Phospholipase D signaling pathway | 1.815E-03 | 3.943E-03 | MAP2K1, CXCR1, AKT1, PIK3R1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05100 | Bacterial invasion of epithelial cells | 1.801E-04 | 5.112E-04 | SRC, PIK3R1, MET, PTK2 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04932 | Non-alcoholic fatty liver disease (NAFLD) | 2.157E-03 | 4.520E-03 | GSK3B, AKT1, PIK3R1, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04630 | Jak-STAT signaling pathway | 2.542E-03 | 5.203E-03 | PIM1, AKT1, STAT6, PIK3R1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05152 | Tuberculosis | 3.898E-03 | 7.795E-03 | CAMK2B, SRC, AKT1, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05168 | Herpes simplex infection | 4.469E-03 | 8.739E-03 | CSNK2A1, CDK1, TP53, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04666 | Fc gamma R-mediated phagocytosis | 4.604E-03 | 8.808E-03 | MAP2K1, AKT1, PIK3R1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04064 | NF-kappa B signaling pathway | 4.604E-03 | 8.808E-03 | CSNK2A1, PTGS2, NFKB1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 3.944E-03 | 7.799E-03 | MAP2K1, SRC, CDK1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04664 | Fc epsilon RI signaling pathway | 1.896E-03 | 4.069E-03 | MAP2K1, AKT1, PIK3R1 |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 1.592E-03 | 3.548E-03 | AKT1, PIK3R1, IGF1R |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 2.146E-03 | 4.520E-03 | CA2, CYP3A4, ABCG2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04150 | mTOR signaling pathway | 1.321E-03 | 3.020E-03 | AKT1, PIK3R1, HIF1A |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.279E-05 | 5.003E-05 | MAOA, CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 1.081E-03 | 2.538E-03 | AKT1, PIK3R1, PTGS2 |
| 09160 Human Diseases | 09161 Cancers | hsa05216 | Thyroid cancer | 4.873E-03 | 9.222E-03 | MAP2K1, TP53 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 3.079E-03 | 6.229E-03 | CA2, CA4 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 1.269E-04 | 3.989E-04 | CYP1A2, XDH |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; PTGS2; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS2; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| NA: NA | Joint and muscular pain | NA | PTGS2; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS2; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| NA: NA | GIST | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; PTGS2; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; FLT3; PTGS2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| NA: NA | Rheumatold arthritis | NA | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
